LABT Lakewood-Amedex Biotherapeutics Inc.
Price Chart
Executive Summary
Lakewood-Amedex Biotherapeutics Inc. (LABT) has completed the effectiveness of its S-1 registration, enabling a direct listing on Nasdaq. The offering involves 4,689,177 shares being resold by existing shareholders, with no proceeds going to the company. This marks the final regulatory step before public trading begins.
Actionable Insight
Traders should monitor the launch of trading for high volatility typical of direct listings, especially given the company's lack of revenue and history of net losses. The absence of underwriters increases execution risk, and early price formation will depend heavily on order imbalances. Watch for RBW's 'ready to trade' signal and the initial Current Reference Price set by Nasdaq.
Key Facts
- S-1 registration has become effective as of April 17, 2026, allowing the company to proceed with its direct listing on Nasdaq.
- 4,689,177 shares of common stock are registered for resale by existing shareholders; the company will not receive any proceeds from the sales.
- This is a direct listing, not a traditional IPO, meaning there is no underwritten offering or new capital raised.
- RBW Capital Partners is serving as financial advisor and is expected to receive 272,219 shares (1.75% of fully diluted shares) as compensation upon closing.
- No public market currently exists for the company's common stock; trading will begin on Nasdaq following the direct listing process.
Financial Impact
No direct financial impact to the company — all proceeds from share sales go to selling shareholders. However, the listing introduces potential share price volatility and future dilution risk if additional shares are issued.
Risk Factors
- Substantial doubt about the company's ability to continue as a going concern, per prior filings.
- High volatility expected due to lack of underwriting and limited public float.
- No new capital raised for the company; financial runway remains dependent on existing resources.
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001238 |
| Document: 9999999995-26-001238-index.html | 9999999995-26-001238 |
| Document: 9999999995-26-001238.txt | 9999999995-26-001238 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
4w ago
|
EFFECT
| $1.96 $0.7700 | ▲ +60.71% | ▲ +60.00% | $0.7700 (+60.71%) |
|
May 6, 2026
5w ago
|
3
| $3.30 $2.95 | ▼ −10.61% | ▼ −12.11% | $0.7700 (−76.67%) |
|
Apr 20, 2026
7w ago
|
EFFECT
| — | awaiting T+5 | — | — |
|
Apr 1, 2026
10w ago
|
S-1/A
| — | awaiting T+5 | — | — |
|
Mar 11, 2026
13w ago
|
S-1/A
| — | awaiting T+5 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access